Sponsors (2)
Introduced February 20, 2025 by Richard Joseph Durbin · Last progress February 20, 2025
The bill strengthens oversight, transparency, and corrective power to reduce harmful or misleading online drug promotion, but it increases compliance costs and enforcement risk, raises privacy and free‑speech concerns for social media users, and leaves some practical uncertainties until guidance is issued.
Patients and consumers (especially those with chronic conditions) will face fewer misleading online drug claims and benefit from quicker manufacturer corrective actions, reducing the risk of harm from inaccurate or unsafe drug promotion.
Taxpayers and the public will gain greater transparency about who is paid to promote drugs and about government enforcement actions through expanded public reporting.
Hospitals, health systems, and regulators will have strengthened detection and response capacity because HHS guidance, surveillance efforts, and additional FDA staff funding improve identification and correction of unsafe or inaccurate online drug promotion.
Social media users (including ordinary individuals) may experience chilled speech and privacy risks because broad influencer definitions plus increased monitoring and analytics (including AI) could deter people from sharing personal experiences and aggregate their public communications.
Healthcare workers, influencers, and small business owners face higher legal risk and compliance costs because civil penalties for promotional posts raise financial and professional exposure.
Manufacturers, providers, and influencers will incur new administrative burdens to report payments under Open Payments/1128G, and taxpayers will fund expanded enforcement (approximately $15M/year).
Based on analysis of 2 sections of legislative text.
Imposes civil liability for influencers and health care providers who post promotional drug content on social media that confers a financial benefit but omits required brief safety/effectiveness summaries; HHS guidance due in 180 days.
Creates a new civil-enforcement rule that holds social media influencers and health care providers liable to the United States for false or misleading promotional communications about certain drugs when those posts provide a financial benefit and fail to include the brief summary of safety and effectiveness required by law. The bill requires the Department of Health and Human Services to issue guidance within 180 days describing how to determine whether a social-media prescription-drug communication is false or misleading and how affected parties can show compliance. The measure defines key terms (including “false or misleading communications” and “social media influencer”), exempts bona fide patient care, medical research, and statements of personal experience or opinion, and ties civil penalties to existing penalty rules already in federal law.